相关实验视频

Updated: Jun 23, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

在前列腺癌中,SLC4A4 是一种新型的酶胺耐药性驱动因素

Hao-Jie Chen¹, Ming-Ming Yu², Jia-Cheng Huang³

¹Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.

|June 16, 2024

概括

前列腺癌中的恩扎胺耐药性是由SLC4A4驱动的,该SLC4A4调解P53乳化. 针对SLC4A4提供了一个有希望的策略,以克服治疗耐药性,并改善晚期前列腺癌患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

先进的前列腺癌 (PCa) 治疗通常涉及像恩扎胺 (Enz) 这样的雄激素受体信号抑制剂 (ARSIs).
对Enz的耐药性是PCa患者死亡的主要原因.
了解恩兹耐药性的机制对于开发有效疗法至关重要.

研究的目的:

确定驱动前列腺癌中恩扎拉胺耐药性的关键分子机制.
调查SLC4A4在Enz耐药性的发展中的作用.

主要方法:

对基因表达综合 (GEO) 数据库的分析,以确定潜在的抗性驱动因素.
研究NF-κB/STAT3/SLC4A4轴及其在P53乳化中的作用.
在体外和体内实验中涉及SLC4A4敲击的实验.

主要成果:

鉴定出SLC4A4是PCa中Enz抵抗的一个新型驱动因素.
长期的恩兹治疗可提高SLC4A4表达的调节.
通过NF-κB/STAT3/SLC4A4轴,SLC4A4调解P53的乳化,促进Enz耐药性和PCa的进展.
在临床前的模型中,SLC4A4的淘汰有效地克服了Enz耐药性.

结论:

在前列腺癌中,SLC4A4 是酶胺耐药性的关键调解者.
准SLC4A4是一种潜在的治疗策略,可以克服Enz耐药性.
对SLC4A4通路的进一步研究可能会导致高级PCa的新型治疗方法.

关键词:

酵素胺是什么酵素胺是什么这是一个PCaPCa.前列腺癌是什么意思前列腺癌是什么意思电阻电阻电阻电阻电阻电阻在SLC4A4A4A4A4A4A4A4A4A4A4

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...